Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.39 +0.42%

+$0.02 today

Market cap
$176.22M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 3.54M

Average 0.45M

IVA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Inventiva S.A.NASDAQ: IVA

Research & Development · Q4 FY2025 · quarter ended Dec 2025

Research & development declines year over year

Q4 FY2025 research & development of €42.96M fell 2.5% year over year. Over 3 fiscal years it compounded at +11.4% a year.

Context

  • Research & development amounted to 1865.0% of revenue in FY2025, up 877.0 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
€42.96M— QoQ
Last fiscal yearDec 2025
€83.61M-8.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.5%——
1 year-8.0%——
3-year CAGR+11.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
83.61M EUR
Year-over-year change
-8.0%
4-year CAGR
+14.6%

Research & Development vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -8.0% is the 5th highest of 10, against a peer median of -12.6%.
  • Research & development amounts to 1865.0% of revenue for IVA, versus a peer median of 843.7%.
IVA Competitors
Research & Development for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M USD-28.3%+10.0%843.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M USD-20.8%-13.4%131.9%
IVAInventiva S.A.FY2025€83.61M EUR-8.0%+11.4%1865.0%
RNACCartesian Therapeutics, Inc.LTM Mar 2026$62.82M USD+25.5%-7.1%3539.3%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$62.37M USD-24.6%-10.1%27721.8%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$60.48M USD+28.2%+38.4%184.8%
IVVDInvivyd, Inc.LTM Mar 2026$58.4M USD-50.0%-40.2%104.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M USD+74.4%+17.0%93235.6%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$40.3M USD-12.6%+4.1%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.18M USD+72.6%+29.4%—
Peer median (excluding IVA) —-12.6%+4.1%843.7%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.19M12.18M17.48M9.2M4.48M
Cost of Revenue1.02M995K(23K)3.88M2.8M
Gross Profit4.19M17.06M17.5M9.2M1.51M
Gross Margin100.0%140.1%100.1%100.0%33.7%
Research & Development48.45M60.47M110.01M90.88M83.61M
Selling, General & Admin11.52M15.5M15.61M17.1M53.89M
Operating Expenses56.31M74.17M120.19M106.76M137.37M
Depreciation & Amortization858K870K2.6M5.2M2.8M
EBITDA(52.76M)(56.29M)(102.04M)(166.53M)(128.15M)
EBITDA Margin-1258.0%-462.2%-583.9%-1810.4%-2858.6%
Operating Income(52.11M)(57.11M)(102.71M)(97.56M)(130.95M)
Operating Margin-1242.6%-468.9%-587.7%-1060.6%-2921.0%
Interest Income57K390K945K1.14M2.83M
Interest Expense138K707K5.18M12.18M32.3M
Other Income / Expenses2.84M2.82M(7.11M)(86.34M)(211.38M)
Income Before Tax(49.27M)(54.29M)(109.82M)(183.9M)(342.33M)
Pre-Tax Margin-1174.8%-445.8%-628.4%-1999.4%-7636.1%
Income Tax Expense364K(20K)607K313K22K
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Net Margin-1183.5%-445.6%-631.8%-2002.7%-7587.8%
EPS (Basic)(1.27)(1.31)(2.43)(3.54)(1.82)
EPS (Diluted)(1.27)(1.31)(2.43)(3.54)(1.82)
Weighted Avg Shares39.17M41.45M45.35M51.98M186.8M
Weighted Avg Shares (Diluted)39.17M41.45M45.35M51.98M186.8M

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.